Protocol Development & Optimisation
Scientific protocol design, feasibility analysis, and endpoint strategy that lay the groundwork for successful clinical trials. Our protocol specialists collaborate with sponsors, investigators, and regulatory experts to craft study protocols that are operationally efficient, scientifically rigorous, and aligned with health authority expectations from the outset.
Building Protocols That Deliver Results
MTK Pharma Services brings together medical, scientific, and operational expertise to develop clinical trial protocols that balance scientific ambition with real-world feasibility. Every protocol we author is shaped by a thorough understanding of the therapeutic landscape, the competitive environment, and the regulatory pathway your programme must navigate.
Our team works alongside your medical and clinical operations staff from the earliest concept stage, helping you define the right study population, select meaningful endpoints, and structure visit schedules that minimise patient burden while capturing the data regulators require. The result is a protocol designed to enrol efficiently, generate high-quality data, and withstand regulatory scrutiny.
End-to-End Protocol Services
Six integrated capability areas that cover every aspect of protocol development — from initial scientific rationale and feasibility through ethics committee submission and investigator alignment.
Protocol Design & Writing
Full protocol authoring grounded in the scientific rationale, therapeutic context, and regulatory requirements specific to your development programme.
- Study objectives and scientific justification
- Inclusion / exclusion criteria definition
- Visit schedule and assessment planning
- ICH E6-compliant document structure
Feasibility Assessment
Data-driven feasibility evaluation that identifies enrolment risks, refines site selection criteria, and validates operational assumptions before study launch.
- Patient population and prevalence analysis
- Competitive landscape assessment
- Country and site capability mapping
- Enrolment rate modelling and projections
Endpoint Strategy
Selection and validation of primary, secondary, and exploratory endpoints that align clinical relevance with regulatory acceptance and statistical power.
- Primary and secondary endpoint selection
- Composite and surrogate endpoint design
- Patient-reported outcome integration
- Regulatory precedent and guidance review
Protocol Amendment Management
Structured amendment processes that minimise disruption to ongoing studies while ensuring all revisions are scientifically justified and properly documented.
- Amendment impact assessment
- Revision tracking and version control
- Regulatory re-submission coordination
- Site notification and training updates
IRB/EC Submission Support
Preparation and coordination of ethics committee and institutional review board submissions to secure timely approvals across multiple jurisdictions.
- Ethics committee submission packages
- Informed consent form development
- Country-specific regulatory dossiers
- Response to ethics committee queries
Investigator Engagement
Structured collaboration with key opinion leaders and principal investigators to strengthen protocol design and build early clinical site commitment.
- KOL advisory board facilitation
- Investigator meeting content development
- Protocol feedback consolidation
- Site-level operational input workshops
Protocol Development Process
A structured, four-stage methodology that transforms your clinical concept into a submission-ready protocol — each stage building on the outputs of the last to ensure scientific coherence, operational viability, and regulatory alignment.
1. Discovery & Planning
Comprehensive review of the therapeutic landscape, competitive intelligence, target product profile, and regulatory pathway. We define the study rationale, target population, and high-level design parameters that will guide protocol authoring.
2. Protocol Authoring
Detailed protocol drafting covering study objectives, design, endpoints, visit schedules, statistical considerations, and safety monitoring. Each section is authored collaboratively with your medical, clinical, and regulatory teams.
3. Stakeholder Review
Structured review cycles with internal teams, scientific advisory boards, and key investigators. Feedback is consolidated, conflicts are resolved, and the protocol is refined to reflect multidisciplinary input and operational realities.
4. Finalisation & Submission
Final quality review, regulatory formatting, and preparation of the complete submission package including the protocol, informed consent, and investigator brochure cross-references for ethics committee and health authority filing.
Why Choose MTK for Protocol Development
A well-designed protocol is the single most important factor in determining whether a clinical trial succeeds. Here is why sponsors trust MTK to get it right.
Medical & Scientific Depth
Our protocol team includes clinicians, pharmacologists, and regulatory scientists who bring therapeutic area knowledge that strengthens every aspect of your study design.
Fewer Amendments
Thorough feasibility analysis and investigator engagement at the design stage dramatically reduce the need for costly mid-study protocol amendments that delay timelines.
Global Regulatory Experience
Protocols authored to satisfy FDA, EMA, MHRA, and other major health authorities simultaneously, reducing rework and enabling parallel global submissions.
Integrated Downstream Planning
Protocol design is coordinated with our data management, biostatistics, and medical writing teams to ensure seamless handover and alignment across all trial workstreams.
Discuss Your Protocol Needs
Whether you are designing a first-in-human study, optimising a pivotal trial protocol, or managing a complex global amendment, our protocol development specialists are ready to help. Contact us to explore how MTK can strengthen your study design from concept through regulatory submission.